TY - JOUR
T1 - Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma
T2 - A case report
AU - Wasano, Koichiro
AU - Sakurai, Kouhei
AU - Kawasaki, Taiji
AU - Kusafuka, Kimihide
AU - Kasahara, Masao
AU - Kondo, Naoki
AU - Inada, Ken Ichi
AU - Ogawa, Kaoru
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by “16K19090 and 18K09545 from Japan Society for the Promotion of Science (JSPS) KAKENHI” and “Aichi Cancer Research Foundation” to Kouhei Sakurai.
Publisher Copyright:
© The Author(s) 2018.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Salivary duct carcinoma is a relatively rare salivary cancer, and most cases are androgen receptor -positive. Salivary duct carcinoma growth is suggested to be androgen dependent, which can reportedly be controlled by androgen deprivation therapy. However, the effectiveness and underlying molecular mechanisms of androgen deprivation therapy for salivary duct carcinoma remain unknown. We report a salivary duct carcinoma case (65-year-old man) arising from the parotid gland with metastasis to the neck lymph nodes and lungs. Androgen deprivation therapy was performed according to the same protocol for prostate cancer treatment. Expression levels of androgen receptor and FOXA1 (forkhead box A1) were immunohistochemically analyzed before and after androgen deprivation therapy. Although the tumor volume was partially diminished during the first 3 months, acquired resistance to androgen deprivation therapy occurred. FOXA1 was not detected in parotid gland after androgen deprivation therapy, whereas androgen receptor expression was positive. FOXA1 expression might be related to acquired androgen deprivation therapy resistance in salivary duct carcinoma.
AB - Salivary duct carcinoma is a relatively rare salivary cancer, and most cases are androgen receptor -positive. Salivary duct carcinoma growth is suggested to be androgen dependent, which can reportedly be controlled by androgen deprivation therapy. However, the effectiveness and underlying molecular mechanisms of androgen deprivation therapy for salivary duct carcinoma remain unknown. We report a salivary duct carcinoma case (65-year-old man) arising from the parotid gland with metastasis to the neck lymph nodes and lungs. Androgen deprivation therapy was performed according to the same protocol for prostate cancer treatment. Expression levels of androgen receptor and FOXA1 (forkhead box A1) were immunohistochemically analyzed before and after androgen deprivation therapy. Although the tumor volume was partially diminished during the first 3 months, acquired resistance to androgen deprivation therapy occurred. FOXA1 was not detected in parotid gland after androgen deprivation therapy, whereas androgen receptor expression was positive. FOXA1 expression might be related to acquired androgen deprivation therapy resistance in salivary duct carcinoma.
KW - Salivary duct carcinoma
KW - androgen deprivation therapy
KW - androgen receptor
KW - forkhead box A1
KW - immunohistochemistry
UR - http://www.scopus.com/inward/record.url?scp=85054662755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054662755&partnerID=8YFLogxK
U2 - 10.1177/2036361318798867
DO - 10.1177/2036361318798867
M3 - Article
AN - SCOPUS:85054662755
VL - 10
JO - Rare Tumors
JF - Rare Tumors
SN - 2036-3605
ER -
